Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 2004

View Archived Issues

Optimized Emt inhibitor shows antiinflammatory activity in vivo

Hemostatic effects of fibrinogen gamma chain dodecapeptide conjugate

Novel VAP-1 inhibitors and their use in macular edema described by Fujisawa

New alpha2C-adrenoceptor antagonists identified at Juvantia

Novel HDAC inhibitors prepared and tested at Oxford GlycoSciences

Ranbaxy researchers present novel muscarinic antagonists

New PKC-theta inhibitors and their use covered by Boehringer Ingelheim patent

Sandoz presents new beta-lactam antibiotic prodrugs

Pharmagene describes furan-based prostanoid EP4 antagonist for migraine therapy

New immunomodulator shows synergistic effect with ciclosporin in mouse heart transplant model

Novel glucagon receptor antagonist by Boehringer Ingelheim

Antinociceptive effects of N-acetylaspartylglutamate peptidase inhibitors in vivo

Combined antiarthritic therapy effective in vivo

New phase IIIb study of Tarceva in advanced NSCLC

Orphan drug designation for ProCord

Schering-Plough and Bayer form strategic alliance

AustCancer acquires North American rights to RP-101

Yentreve launched in Europe

Safinamide studied in phase III trial for Parkinson's

TheraCLEC selected for CMA Pilot 2 program

Mirus Bio enters into research agreement with Genzyme

Phase I trial investigates GVAX prostate cancer vaccine with MDX-010

CollaGenex files for trademark Oracea for rosacea treatment Col-101

Oncomer converts solitary tumor into bloodless mass

Iressa studied in new head-to-head trial for NSCLC

AnorMED to seek SPA for AMD-3100 phase III trials

New data on the therapeutic benefits of exenatide in diabetes

SPA for phase III study of glufosfamide for metastatic pancreatic cancer

FK-778 shows efficacy as an immunosuppressant in a liver transplantation model

Valeant acquires E.U. rights to Tasmar

5-alpha Avocuta active in seborrhea

EO-1606 shows promise in multiple dermatological disease models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...